Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
OBJECTIVE
To compare pure hormonal treatment (orchiectomy plus flutamide) versus hormonal plus cytostatic treatment (orchiectomy plus estramustine phosphate [EMP]) as first-line therapy for advanced prostatic cancer.


METHODS
From October 1985 to December 1991 a total of 99 patients were enrolled: 49 received orchiectomy plus EMP, 2 x 280 mg/day; 50 received orchiectomy plus flutamide, 3 x 250 mg/day.


RESULTS
Of the 99 enrolled patients, 93 were evaluable for toxicity and 82 for efficacy. The median time to progression was 161 weeks for EMP versus 120 weeks for flutamide (p = 0.75, not significant). For distant metastases, bone pain, and poor performance status, treatment with EMP showed significantly better results than the flutamide group. The most frequent side effects were gastrointestinal for EMP and hot flushes for flutamide.


CONCLUSIONS
For patients with advanced undifferentiated prostatic cancer and poor prognostic factors, treatment with EMP seems to show significant benefit.
Roessler
W
W
Department of Urology, Hospital St. Josef, Regensburg, Germany.
Hinke
A
A
Wieland
W F
WF
D000368:Aged; D003131:Combined Modality Therapy; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors; D013997:Time Factors
D004961:Estramustine; D005485:Flutamide